A CRISPR screen identifies MAPK7 as a target for combination with MEK inhibition in KRAS mutant NSCLC

Mutant KRAS represents one of the most frequently observed oncogenes in NSCLC, yet no therapies are approved for tumors that express activated KRAS variants. While there is strong rationale for the use of MEK inhibitors to treat tumors with activated RAS/MAPK signaling, these have proven ineffective...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:PLoS One
Main Authors: Dompe, Nicholas, Klijn, Christiaan, Watson, Sara A., Leng, Katherine, Port, Jenna, Cuellar, Trinna, Watanabe, Colin, Haley, Benjamin, Neve, Richard, Evangelista, Marie, Stokoe, David
Formato: Artigo
Idioma:Inglês
Publicado em: Public Library of Science 2018
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6005515/
https://ncbi.nlm.nih.gov/pubmed/29912950
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pone.0199264
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados